Attenuated effect of zinc gluconate on oxidative stress, inflammation, and angiogenic imbalance in pre-eclampsia rats.

AIMS: Pre-eclampsia (PE) is a common obstetric disease associated with oxidative stress, systemic inflammation, and angiogenic imbalance, whereas zinc (Zn) presents anti-oxidative and anti-inflammatory effects. This study is to investigate whether zinc gluconate (ZG) supplementation may ameliorate the early signs, adverse pregnancy outcomes, and pathogenic processes of PE in an animal model. MAIN METHODS: Forty pregnant Wistar rats were randomly divided into four groups: blank control (treated with normal saline, NS), Zn control (treated with ZG and followed by NS), PE model (treated with NS and followed by nitro-L-arginine methyl ester, L-NAME), and PE intervention (treated with ZG and followed by L-NAME). ZG (5 mg/kg/day) or NS was administered by gavage from day 0 to 19 of gestation, and L-NAME (80 mg/kg/day) or NS was subcutaneously injected from day 4 to 19 of gestation. The blood pressure, urinary protein, and pregnancy outcomes were recorded. Oxidative stress, inflammation, and angiogenic homeostasis were evaluated. KEY FINDINGS: PE rats exhibited oxidative stress (reduced SOD, CAT, and GSH, and increased MDA and 3-NT), inflammation (increased IL-6 and TNF-α), and angiogenic imbalance (reduced VEGF and PlGF, and increased sFlt-1). After intervention with ZG, the blood pressure and urinary protein levels were reverted, and the pregnancy outcomes were improved. The oxidative stress, inflammation, and angiogenic imbalance were effectively restored in accompany by increased Zn and MT levels. SIGNIFICANCE: ZG can ameliorate the early signs and pathological processes of PE in the animal model, indicating the value of zinc supplementation during pregnancy for PE prevention.

Gestational Folic Acid Administration Alleviated Maternal Postpartum Emotional and Cognitive Dysfunction in Mice.

Gestational folic acid (FA) supplementation has been widely recognized for its benefits in preventing offspring defects, but its effect on postpartum females has not yet been adequately assessed. The occurrence of emotional and cognitive dysfunction is common in postpartum women, and its treatment remains limited. Considering the promising results of FA in various psychiatric disorders both in human and redents, we tested the effect of gestational FA administration on postpartum psychiatric behavioral phenotypes and the implicated brain-related mechanisms in a murine model. FA was administered orally in both the hormone-stimulated-pregnancy (HSP) model and pregnant mice at doses of 1 and 5 mg/kg. Postpartum behavioral results showed that the disorders of cognitive performance, depressive, and anxiety-related behaviors were all alleviated in the 5 mg/kg FA group. However, the general development of their offspring remained unaffected. Immunofluorescence and immunoblot results revealed that FA pretreatment significantly activated the maternal hippocampal BDNF-related pathway. Morphological studies have confirmed that FA promotes hippocampal neurogenesis. Moreover, synaptic plasticity and synaptic transmission are enhanced. All of these hippocampal changes play critical roles in rescuing neuronal function and behaviors. Thus, our data suggest that gestational FA administration has a therapeutic effect that improves cognition and reduces depression and anxiety in a murine postpartum model. This may be developed as a preventive and adjuvant therapeutic option for pregnant women.